Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. Issue 12 (2nd December 2018)

• Record Type: Journal Article
• Authors: Zaja, Francesco; Salvi, Flavia; Rossi, Maura; Sabattini, Elena; Evangelista, Andrea; Ciccone, Giovannino; Angelucci, Emanuele; Gaidano, Gianluca; Zanni, Manuela; Ladetto, Marco; Chiappella, Annalisa; Vitolo, Umberto; Zinzani, Pier Luigi; Califano, Catello; Tucci, Alessandra; Patti, Caterina; Pileri, Stefano A.; Lenti, Valentina; Piccaluga, Pier Paolo; Cavallo, Federica; Volpetti, Stefano; Perali, Giulia; Assouline, Sarit; Mann, Koren Kathleen; Morin, Ryan; Alcaide, Miguel; Bushell, Kevin; Fanin, Renato; Levis, Alessandro
• Is Part Of: Leukemia & lymphoma. Volume 59:Issue 12(2018)
• Page Start: 2904
• Page End: 2910
• Publication Date: 2018-12-02
• Subjects: Diffuse large B-cell lymphoma -- panobinostat -- relapsed/refractory -- genomic; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2018.1452208
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: We investigated panobinostat 40 mg three times weekly in 35 adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Overall response rate and complete response were 17.1% and 11.4%, respectively. Median progression-free survival (PFS) and overall survival were 2.4 and 7.6 months, respectively. Calculated 12, 24 and 36 months PFS were 26%, 11% and 11%, respectively. Four patients who achieved a sustained CR, continued receiving panobinostat for an overall period of 44, 48, 50, 62 months. Thrombocytopenia grade 3 (5 patients) and 4 (24 patients) represented the main toxic effect, causing dose reduction or treatment suspension in 19 patients. Genomic analysis was unable to identify any relationship between mutations and response; TP53 mutation appeared not to impact the clinical outcome. Overall, panobinostat has a modest activity in R/R DLBCL patients, however it can induce very long lasting responses in some cases. Thrombocytopenia frequently limits the use of this agent.